Hypertension in young adults with obesity: new mechanisms and therapeutic options
Key words: adulthood, hypertension, obesity, pathophysiology, treatment
CC BY 4.0
Hypertension in young adults with obesity: new mechanisms and therapeutic options
CC BY 4.0
Hypertension is a leading global cause of morbidity and mortality, increasingly prevalent among young adults with obesity. This epidemiologic shift is particularly concerning, as early‑onset hypertension confers an increased lifetime risk of cardiovascular disease. Obesity and hypertension share pathophysiological mechanisms, including sympathetic nervous system overactivation, leptin resistance, chronic low‑grade inflammation, renal fat deposition, endothelial dysfunction, and genetic predisposition. Dietary factors, sedentary lifestyle, poor sleep, psychosocial stress, and environmental exposures further exacerbate the risk. Hence, effective management requires an integrated approach targeting both obesity and blood pressure. Lifestyle interventions play a key role in therapy but are often hindered by poor adherence in younger populations. Pharmacological therapies have shown substantial efficacy in reducing weight and blood pressure, with emerging cardiovascular benefits. Bariatric surgery remains an alternative, achieving sustained weight loss and remission of hypertension in a significant proportion of patients. Early, multifaceted interventions tailored to this population can reduce premature cardiovascular disease, lower health care costs, and improve quality of life.
Introduction
Hypertension remains one of the leading global contributors to morbidity and mortality, accounting for more than 10 million deaths annually, primarily through its association with cardiovascular disease (CVD), stroke, and chronic kidney disease.1 While traditionally considered a disorder of middle‑aged and older adults, hypertension is also increasingly diagnosed in younger age groups.2 This epidemiologic shift is concerning, because early‑onset hypertension has been shown to confer a higher lifetime risk of CVD, as compared with hypertension developing later in life.3
The global prevalence of obesity has nearly tripled since 1975, and statistics indicate that more than 1 billion people worldwide will be living with obesity by 2030.4 Among adolescents and young adults, the rates of overweight and obesity are increasing alarmingly fast, particularly in high‑income and rapidly developing low- and middle‑income countries.5 However, even in individuals with normal weight, high waist circumference—as an indicator of adiposity—was significantly associated with an increased prevalence of hypertension.6 Parallel to this trend, hypertension is now among the most common comorbidities observed in young adults with obesity, with some studies estimating prevalence rates at 20%–30% in this population, while the rates are generally lower for nonobese young adults.7 Importantly, obesity and hypertension exhibit a strong relationship, with excessive adiposity acting as a determinant of elevated blood pressure (BP) via multiple neurohormonal, renal, vascular, and inflammatory mechanisms.8
For the purposes of this review, “young adults” are defined as individuals aged 18–39 years, consistent with major epidemiologic cohorts.3 Estimates of hypertension prevalence in young adults vary widely; a recent global review9 suggests a prevalence between 3.7% and 8.6%, depending on the region and definition, with substantially higher rates observed among individuals with obesity (defined as a body mass index [BMI] ≥30 kg/m²). For example, United States data from a recent National Health and Nutrition Examination Survey (NHANES) report a prevalence of approximately 23% in this age group.10 Similarly, data from a Polish registry corroborate these findings in the European populations. This combination of obesity and hypertension in young adults is particularly worrisome, because it accelerates vascular aging and increases the lifetime risk of CVD. Evidence from cohort studies suggests that young adults with obesity‑related hypertension are more likely to develop left ventricular hypertrophy, arterial stiffness, and early atherosclerotic lesions than lean normotensives.12,13 The additive effect of obesity and high BP also appears to magnify the risk of premature coronary heart disease, heart failure, and stroke.14 Thus, identifying and treating hypertension in obese young adults is not simply about BP control but about long‑term cardiovascular protection.
Despite this growing clinical problem, current management strategies remain suboptimal. While lifestyle modifications—dietary changes, physical activity, and weight loss—remain the main therapy, adherence is often poor in young populations and BP reduction is variable.15 Conventional antihypertensive medications are effective, but questions remain about whether standard treatment approaches adequately address the specific pathophysiological mechanisms of obesity‑related hypertension, such as sympathetic overactivation, leptin resistance, or inappropriate activation of the renin‑angiotensin‑aldosterone system (RAAS).16 Moreover, novel treatments, such as glucagon‑like peptide‑1 receptor agonists or dual incretin therapies, have emerged as promising options to address both obesity and hypertension simultaneously.17,18
All things considered, there is an urgent need to deepen our understanding of the underlying pathophysiology and to explore treatment strategies. Such efforts are critical not only for BP control but also for preventing premature CVD and reducing health care costs over the long term.
Thus, the objective of this narrative review, incorporating scoping elements, is to comprehensively examine the existing literature—spanning preclinical, clinical, and translational studies—related to hypertension and obesity in young adults. Due to limited direct evidence in this specific population, the review draws on a combination of direct findings and cautious extrapolation or indirect conclusions based on expert interpretation to provide a broad understanding of the topic. At the same time, this approach acknowledges its limitations and aims to identify critical gaps in the literature, thereby guiding future research priorities in this growing field.
Pathophysiology of obesity‑induced hypertension in young adults
Leptin
Leptin is a 16 kD hormone mainly produced in the adipose tissue, in quantities proportional to the accumulated fat, and serving as an important regulator of energy expenditure, promoting satiety and weight loss.19,20 It is tightly linked to a plethora of body functions ranging from the menstrual cycle21 to the regulation of the immune system,22 but perhaps the bulk of the research has been centered around the association of leptin and obesity‑induced hypertension. Specifically, studies in large human populations have positively correlated high plasma levels of leptin with an increased risk of hypertension.23,24
The role of the sympathetic nervous system (SNS) has been extensively studied. Muscle sympathetic nerve activity, a surrogate for SNS activation, demonstrates a strong positive correlation with plasma leptin levels in healthy humans.25 The central action of leptin was shown by Rahmouni et al26 in an experiment where intracerebroventricular leptin infusion increased mean BP, while the same effects were observed after microinjections of leptin directly into the hypothalamic arcuate nucleus. This discovery led to the eventual isolation of leptin receptor in the hypothalamic arcuate nucleus, while a different set of experiments clarified the roles of the proopiomelanocortin and agouti‑related peptide neurons in the central actions of leptin.25,27-30
There is also evidence to support a clinically significant brain RAAS‑leptin interaction that facilitates renal and brown adipose tissue SNS activation, while not interfering with leptin’s actions on food intake.31
Inflammation
Obesity is increasingly recognized as a state of chronic, low‑grade inflammation that contributes to the early development of hypertension in young adults.32,33 As lipocytes grow larger and larger through hypertrophy, the surrounding microenvironment becomes even more hypoxic due to decreased vascularization. This in turn leads to cell death, cell dysfunction, and the eventual infiltration of the adipose tissue by immune cells. Normal adipose tissue contains 5% of macrophages, a percentage that dramatically increases to approximately 50% in situations of substantial lipocyte hypertrophy and tissue hypoxia.34-36 This quantitative increase in macrophages is also accompanied by the secretion of proinflammatory cytokines, such as tumor necrosis factor α (TNF-α) and interleukin 6 (IL‑6), which impair endothelial nitric oxide (NO) bioavailability and promote vascular dysfunction.37,38 Through the actions of hypoxia‑inducible factor 1, a switch occurs leading to the transition from oxidative phosphorylation to glycolysis and to the eventual acquisition of a proinflammatory M1‑like phenotype.35 These inflammatory mediators also activate the SNS and the RAAS, increasing vascular tone and renal sodium retention.8,39 Elevated inflammatory markers, including C‑reactive protein (CRP), correlate with increased BP and early arterial stiffness in obese young adults. The diversity of the immune response expands further, with the concomitant contribution of cells from the adaptive immune system.40-42 Newer evidence suggests that the inflammatory processes are not limited to the adipose tissue but also occur in the hypothalamic areas responsible for energy expenditure and homeostasis.43
Renal fat
The term “renal fat” includes both perirenal adipose tissue (PRAT), stored between the renal parenchyma and Gerota facia, and renal sinus fat, found in the renal hilum, the area of the kidney where most of the renal vessels, nerves, and lymphatics are located.44 Excess renal sinus and perirenal fat in obesity exert both mechanical and endocrine effects that promote hypertension.8,45 Mechanical compression of the renal parenchyma and vasculature by ectopic fat increases renal interstitial pressure, impairs natriuresis, and stimulates tubular sodium reabsorption.46 In parallel, adipose tissue within the renal sinus produces proinflammatory cytokines and angiotensinogen, activating the RAAS and enhancing oxidative stress, which contribute to glomerular hyperfiltration and sodium retention. These changes combine with obesity‑related sympathetic overactivity to raise renal vascular resistance and systemic BP.47
A large‑scale epidemiologic study, concluded in 2011 by Foster et al45 and involving the population of the Framingham Heart Study (n = 2923), confirmed this pathophysiology. Researchers found associations between renal fat and an increased hypertension risk and chronic kidney disease, consequently supporting the possible role of renal fat in obesity‑related hypertension. In 2015, De Pergolia et al48 showed a significant correlation between perirenal ultrasonic fat thickness and a plethora of anthropometric / metabolic parameters, including waist circumference, fasting insulin, insulin resistance, and 24‑hour mean diastolic BP, in a population of 42 obese patients.
Recently, by suppressing a well‑known antihypertensive mediator, researchers managed to show that afferent nerves in PRAT are central to the pathogenesis of hypertension in mice.49 Responsible for this maladaptive response are the L1–L2 dorsal root ganglia neurons, and the bilateral PRAT ablation / denervation led to sustained BP reductions.
Endothelial dysfunction
Excess adiposity promotes endothelial dysfunction, a key mechanism linking obesity to hypertension.50 Adipose tissue inflammation releases TNF-α, IL‑6, and free fatty acids, which increase reactive oxygen species and reduce NO bioavailability, impairing vasodilation.51 Hyperleptinemia and insulin resistance further stimulate endothelial nicotinamide adenine dinucleotide phosphate oxidase, enhancing oxidative stress and vascular stiffness.52 In addition, obesity activates the RAAS, and angiotensin II promotes endothelial inflammation, oxidative stress, and vascular remodeling.53 Together, these changes lead to reduced endothelium‑dependent vasodilation, increased vascular tone, and early arterial stiffness, contributing to hypertension in young adults with obesity.50-55
Fructose and uric acid
Increased consumption of sugar‑sweetened beverages leads to higher uric acid levels and systolic BP, as demonstrated in a cross‑sectional analysis of the NHANES, which included over 4000 adolescents.56 Murine models showed that fructose‑induced hypertension largely depends on an increased jejunal NaCl/H2O absorption in concert with reduced renal NaCl secretion, an effect predominantly mediated by the apical Cl-/bicarbonate exchanger Slc26a6 (proton‑coupled amino acid transporter 1). Mice knocked out for this gene did not develop fructose‑induced hypertension.57,58
Fructose‑induced hyperuricemia is caused by phosphorylation of fructose by fructokinase. This process leads to adenosine triphosphate consumption and subsequent adenosine monophosphate production, which can be further metabolized to uric acid.58 A murine model using fructose‑fed and control mice, demonstrated the efficacy of febuxostat, a xanthine oxidase inhibitor, in lowering triglyceride and insulin levels vs placebo, while the difference in systolic BP lowering efficacy was nonsignificant.59
Genetics
A great deal of ongoing research, mainly in the form of genome‑wide association studies (GWAS), is trying to elucidate the genetic substrate of obesity and its many links to other pathological states, such as hypertension, cancer, etc.60 Around 300 single‑nucleotide polymorphisms have been found to correlate with visceral adiposity, waist‑to‑hip ratio, and extreme obesity, although these loci only explain a small percentage (2%–7%) of the data variance.61 GWAS have identified variants in the FTO, MC4R, and LEPR genes that increase the obesity risk and indirectly raise BP via enhanced appetite and adiposity.61,62 Other loci, such as CYP17A1, UMOD, and NPPA/NPPB, affect renal sodium reabsorption, natriuretic peptide signaling, and RAAS activity, directly influencing BP in obese individuals.63,64 Additionally, polymorphisms in the AGT, ACE, and ADRB2 genes are linked to heightened sympathetic and RAAS activation, amplifying obesity‑induced hypertension.65 These findings suggest that polygenic susceptibility interacts with environmental factors, such as diet and physical inactivity, to accelerate the development of hypertension in young adults with obesity.61-67
Risk factors of hypertension in obese young adults
Recent guidelines from the European Society of Cardiology and the American Heart Association / American College of Cardiology emphasize a comprehensive approach to managing hypertension in young adults with obesity.68,69 This includes screening for secondary causes of hypertension, assessment for obstructive sleep apnea (OSA), and prioritization of lifestyle and weight‑loss interventions. Pharmacological treatment decisions should consider age‑specific factors and often involve combination therapy tailored to young adults. Equally important is identifying and characterizing the key risk factors driving obesity‑related hypertension in this population, which we explore in the following sections.
Psychosocial factors
Psychosocial stress plays a significant role in the development of hypertension in young adults with obesity, acting through neuroendocrine and behavioral pathways.70 Chronic stress, adverse childhood experiences, and social disadvantage lead to sustained hypothalamic–pituitary–adrenal (HPA) axis activation and SNS overdrive, raising BP and promoting visceral adiposity.71 Depression and anxiety, highly prevalent in youth with obesity, are associated with increased levels of inflammatory cytokines and cortisol dysregulation, which can exacerbate vascular dysfunction and sodium retention.70-74
Sedentary life
Sedentary lifestyle is an important, independent contributor to the development of hypertension in young adults with obesity.75 Prolonged sitting and low physical activity reduce insulin sensitivity and NO bioavailability, promoting endothelial dysfunction and arterial stiffness.76,77 Physical inactivity also exacerbates weight gain, visceral adiposity, and low‑grade inflammation, activating SNS and RAAS.8,78 Young adults with obesity, who spend more time sitting, exhibit higher BP, impaired autonomic balance, and a greater risk of developing sustained hypertension than their active peers.79 Increasing daily moderate‑to‑vigorous activity and reducing sitting time have been shown to improve vascular function and lower BP, even without significant weight loss.8,75-78,80
Nutrition
Diets rich in refined carbohydrates, added sugars, and saturated fats promote weight gain, insulin resistance, and low‑grade inflammation, which increase sympathetic activity and impair vascular function.81,82 High sodium content, common in processed foods, directly elevates BP by increasing extracellular fluid volume and enhancing RAAS activation.81-86 In contrast, Steffen et al,87 drawing on data from the CARDIA (Coronary Artery Risk Development in Young Adults) study, provided robust evidence supporting the protective and BP‑lowering effects of plant‑based diets. Furthermore, the attenuating effects of the Dietary Approaches to Stop Hypertension diet on BP were evident 2 weeks after the initiation of the trial.88 This significant result has since been validated by multiple randomized controlled trials and meta‑analyses.89,90
Sleep
Short sleep duration (<6 h/night) increases SNS activity, cortisol release, and RAAS activation, while reducing nocturnal BP dipping.91 Sleep deprivation also worsens insulin resistance, leptin–ghrelin imbalance, and appetite regulation, promoting further weight gain and visceral adiposity.92 In obesity, OSA—prevalent even in young adults—causes intermittent hypoxia, oxidative stress, and endothelial dysfunction, all of which elevate BP.93
Indeed, some of the most important prospective cohort studies ever designed, the CARDIA, the NHANES, and the Whitehall II (Social and Occupational Influences On Health and Illness), have consistently linked short sleep duration (≤5 h/night) with increased systolic BP.94-97 On the other side of the spectrum, the Sleep Heart Health Study found that people who sleep longer than 9 hours per night tend to have higher systolic BP than those who get the recommended 7 to 8 hours of sleep.98
Environment
Exposure to high levels of traffic noise has been shown to have detrimental effects on the overall individual cardiovascular health. After adjusting for the many confounding factors of daily life, researchers found that a 10 dB‑increase in noise exposure led to higher values of systolic BP.99 Daytime noise levels exceeding 70 dB were also associated with a significantly increased risk of myocardial infarction, as compared with levels below 60 dB.100
According to the Global Burden of Disease study, pollution due to particulate matter (PM) is a rapidly emerging global risk factor for public health.101 Further research showed a close relationship between increased PM concentrations and BP.102-108 There is also compelling evidence suggesting that wearing a highly efficient face mask capable of blocking PM may lead to significant reductions in ambulatory BP.109
All the above are the result of shared biological pathways, including oxidative stress, systemic inflammation, and SNS imbalance, leading to vasoconstriction, vascular dysfunction, and hypertension, but also activating stress hormones (cortisol, adrenaline) and promoting fat storage, especially abdominal fat, which worsens obesity and hypertension.110
Treatment options for young adults with obesity and hypertension
Effective management of obesity, through lifestyle modification, pharmacotherapy, or bariatric surgery, not only induces substantial weight loss but also yields clinically meaningful reductions in BP, concurrently addressing 2 major cardiovascular risk factors. Early initiation of obesity treatment, including in young adults, can yield substantial reductions in weight and BP, potentially preventing complications. Treating obesity and hypertension at early stages is also the most cost‑effective strategy, highlighting the importance of intervention in early adulthood, if not sooner (as obese children and teenagers often become obese adults).111
While antiobesity interventions have demonstrated antihypertensive effects, it is important to note that these effects are generally reported as secondary outcomes in weight‑loss trials rather than primary end points. Furthermore, the majority of these trials have been conducted in mixed‑age adult populations, with limited data specifically addressing young adults with obesity‑related hypertension. Consequently, the direct impact of these interventions on BP in this younger demographic is primarily extrapolated from broader populations until dedicated clinical studies focusing on young adults are conducted.
However, it is certain that lifestyle interventions remain foundational. Meta‑analytic data indicate that even modest reductions in BMI improve BP: a 2.27 kg/m2 decrease in BMI corresponds to reductions in clinic systolic BP (SBP) of 5.79 mm Hg and diastolic BP (DBP) of 3.36 mm Hg, whereas a 4.12 kg/m2 BMI reduction produces larger declines of 6.65 mm Hg (SBP) and 3.63 mm Hg (DBP).112 BMI reductions of 3 kg/m2 or more amplify these effects, highlighting a dose–response relationship. Dietary strategies emphasizing fruits, vegetables, sodium restriction, and Mediterranean‑style patterns further lower BP in overweight and obese adults.113 Physical activity provides complementary benefits, reducing incident hypertension and lowering BP across the spectrum from normotension to established hypertension, with the greatest effect observed in prehypertensive individuals.114 Specifically, young adults with obesity and hypertension should aim for at least 150 minutes of moderate‑intensity aerobic exercise weekly, such as brisk walking or cycling, while tailoring the intensity and type of activity based on individual health status and comorbidities (eg, diabetes mellitus type). Strength training should be included on 2 days per week, with exercises and loads adjusted to accommodate any musculoskeletal limitations, ideally under professional guidance to ensure safety and effectiveness.115
Psychosocial stress exacerbates both obesity and hypertension via activation of the SNS and HPA axis, promoting inflammation, cortisol dysregulation, and hyperinsulinemia. Poor sleep, depression, and social isolation compound cardiovascular risk and hinder weight management. Interventions including structured exercise, mindfulness, meditation, deep‑breathing exercises, social support, and professional counseling improve psychological well‑being, facilitate weight loss, and contribute to BP reduction.116
Pharmacotherapy for obesity is indicated when lifestyle measures are insufficient. Five agents are currently approved by the European Medicines Agency for nonsyndromic obesity: orlistat, naltrexone / bupropion, liraglutide, semaglutide, and tirzepatide.117 Orlistat showed modest BP reductions of about 2.5 mm Hg for SBP and 2 mm Hg for DBP, while naltrexone / bupropion showed no difference in comparison to placebo.118
Semaglutide (2.4 mg weekly) produced a mean weight loss of 14.9% over 68 weeks in STEP 1 (Semaglutide Treatment Effect in People with Obesity) study, with at least 5% reduction achieved by 83.5% of the participants.119 The STEP 5 (Two‑year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity) trial confirmed long‑term efficacy and safety over 2 years.120 In the SELECT (Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity) trial, semaglutide reduced major adverse cardiovascular events in obese adults without diabetes.121 Additional trials demonstrate benefits in knee osteoarthritis (STEP 9; Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis),122 heart failure (STEP‑HFpEF; Semaglutide Treatment Effect in People with Obesity and Heart Failure with Preserved Ejection Fraction),123 and metabolic‑associated steatohepatitis.124
Tirzepatide achieved mean weight loss of 20.9% with a 15 mg weekly dose in the SURMOUNT‑1 (A Study of Tirzepatide [LY3298176] in Participants With Obesity or Overweight) trial, with at least 5% weight loss in 90.9% of the participants.125 The SURMOUNT‑5 (A Study of Tirzepatide [LY3298176] in Participants With Obesity or Overweight With Weight Related Comorbidities) trial demonstrated superior weight reduction vs semaglutide 2.4 mg weekly.126 Cardiovascular outcomes are being evaluated in the ongoing SURPASS‑CVOT (A Study of Tirzepatide [LY3298176] Compared with Dulaglutide on Major Cardiovascular Events in Participants with Type 2 Diabetes) trial127 and SURMOUNT MMO (A Study of Tirzepatide [LY3298176] on the Reduction on Morbidity and Mortality in Adults with Obesity) trial.128 Tirzepatide also improves OSA in obese patients, as shown in the SURMOUNT‑OSA (A Study of Tirzepatide [LY3298176] in Participants with Obstructive Sleep Apnea) trial, leading to Food and Drug Administration approval for this indication.129
Both semaglutide and tirzepatide lower BP. In randomized trials, semaglutide reduced SBP by 5.1 mm Hg (–6.16 vs –1.06 mm Hg placebo), while tirzepatide reduced SBP by 6.2 mm Hg (–7.2 vs –1 mm Hg placebo; Table 1).119,125 These agents favorably influence metabolic and cardiovascular parameters through mechanisms including natriuresis, improved endothelial function, and reduced arterial stiffness, with minimal adverse hemodynamic effects.119,125,130
Study and duration | Drug | Population | Mean weight loss, % | Placebo‑controlled BP change, mm Hg | Notes / key findings |
Abbreviations: CV, cardiovascular; CVD, cardiovascular disease; DBP, diastolic blood pressure; SBP, systolic blood pressure | |||||
SCALE130; 56 wks | Liraglutide, 3 mg daily | Adults with obesity | 8 | SBP, –2.8 (95% CI, –3.56 to –2.09);
DBP, –0.9 (95% CI, –1.41 to –0.37) | Significant but modest BP reductions, supports an adjunct role in hypertension management |
STEP 1119; 68 wks | Semaglutide, 2.4 mg weekly | Adults with obesity | 14.9 | SBP placebo‑adjusted,
–5.1 (–6.16 vs –1.06) | Substantial weight loss, meaningful systolic BP reduction |
SELECT121; 104 wks | Semaglutide, 2.4 mg weekly | Nondiabetic patients with obesity and CVD | 9.39 | SBP, –3.31; DBP, –0.55 | Confirms preferential effects on SBP in a high‑risk population, moderate weight loss observed in this population |
SURMOUNT125; 72 wks | Tirzepatide, 15 mg weekly | Adults with obesity | 20.9 | SBP placebo‑adjusted,
–6.2 (–7.2 vs –1) | Superior weight loss and systolic BP reduction, long‑term CV outcomes pending |
Bariatric surgery offers the most intensive intervention. The GATEWAY (Gastric Bypass to Treat Obese Patients With Steady Hypertension) trial reported hypertension remission in 45.8%–51% of patients postoperatively.131 A systematic review showed superior long‑term hypertension remission with Roux‑en‑Y gastric bypass vs sleeve gastrectomy, despite similar BP reductions, indicating additional metabolic and neurohumoral benefits.132 Finally, a recent publication in the field using data from the Veterans Health Administration Antihypertensives in Obesity Management Cohort, showed that patients treated surgically demonstrated significantly better BP control over a median follow‑up of 5.1 years. More specifically, as compared with patients on medical treatment only, those who received metabolic bariatric surgery had lower SBP/DBP by an average of 5.4/1.8 mm Hg, and presented a 32% higher likelihood of complete discontinuation of antihypertensive medications.133 Regarding the treatment of hypertension in obesity, there are no special guidelines, but the choice must be based on the pharmacokinetics and pharmacodynamics of each drug category. Angiotensin‑converting enzyme inhibitors and angiotensin receptor blockers could be recommended as first‑line options in obese hypertensive patients, because they target the RAAS, which is upregulated in obesity, and tend to have neutral or beneficial effects on insulin sensitivity and metabolic profile, as compared with other drug classes. Calcium channel blockers also have a relatively neutral metabolic profile and could be used as add‑on therapy without worsening glucose metabolism or weight gain. Diuretics remain effective for BP control due to their ability to reduce sodium retention and volume overload common in obesity, but they are associated with potential metabolic side effects, such as dysglycemia and electrolyte disturbances, which may be more concerning in patients already at a risk for metabolic syndrome. Traditional β-blockers have been linked to weight gain and adverse effects on insulin resistance, but nebivolol134 seems to have a neutral or even beneficial impact on insulin and lipid metabolism. Overall, treatment should balance effective BP lowering with careful consideration of metabolic effects.135,136
Discussion
This review focuses on young adults; however, much of the mechanistic evidence cited—such as studies on leptin signaling, renal adiposity, endothelial dysfunction, and inflammatory pathways—originates from animal models or adult populations that are older or of mixed age. The extrapolation of these findings to young adults should be approached cautiously, as age‑related physiological differences may influence pathophysiological processes and treatment responses.
Moreover, direct, age‑specific data in young adults are often limited or unavailable, particularly regarding environmental exposures, dietary patterns, and long‑term outcomes of pharmacotherapies. Consequently, some conclusions rely on indirect evidence or expert interpretation, which may not fully capture the nuances of hypertension development in this younger demographic.
Given these limitations, key research priorities include: 1) conducting longitudinal and mechanistic studies specifically in young adults with obesity‑related hypertension, 2) clarifying age‑specific pathways that distinguish early‑onset hypertension, and 3) evaluating the efficacy and safety of emerging obesity pharmacotherapies with BP end points in this population. Addressing these gaps is essential to optimize prevention and management strategies tailored to young adults. Looking ahead, a multifaceted approach to preventing and managing obesity‑related hypertension in young adults is critical. Beyond lifestyle interventions—such as diet, physical activity, and behavioral strategies—novel pharmacotherapies, including dual and triple incretin agonists and amylin receptor agonists, hold great potential for targeting both obesity and BP control. Device‑based therapies may offer alternative or adjunctive options for selected patients. Moreover, advancing technologies, such as digital twins and precision medicine offer a promise of personalized risk prediction, treatment optimization, and early intervention tailored to individual patient profiles. However, robust, young adult–focused research is needed to validate and implement these strategies effectively, ultimately reducing the long‑term cardiovascular burden in this growing population.
Conclusions
To conclude, obesity‑related hypertension in young adults represents a critical and growing public health challenge, driven by complex interactions based on hormonal, inflammatory, renal, and vascular mechanisms. This dual burden accelerates cardiovascular aging, increases lifetime CVD risk, and demands early and effective interventions. While lifestyle modifications play a main role, novel pharmacotherapies have been introduced recently. Addressing obesity‑induced hypertension in young adults offers the opportunity to reduce premature morbidity, mortality, and health care costs, underscoring the importance of comprehensive treatment strategies.
- NCD Risk Factor Collaboration (NCD‑RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population‑representative studies with 104 million participants. Lancet. 2021; 398: 957‑980. | Crossref
- Flynn JT, Kaelber DC, Baker‑Smith CM, et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics. 2017; 140: e20171904. | Crossref
- Yano Y, Reis JP, Colangelo LA, et al. Association of blood pressure classification in young adults using the 2017 American College of Cardiology / American Heart Association Blood Pressure Guideline With Cardiovascular Events Later in Life. JAMA. 2018; 320: 1774‑1782. | Crossref
- World Health Organization. WHO European Regional Obesity Report 2022. Geneva: WHO; 2022. https://www.who.int/news/item/04‑03‑2022‑who‑2022‑obesity‑report. Accessed November 23, 2025.
- NCD Risk Factor Collaboration (NCD‑RisC). Worldwide trends in body‑mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population‑based measurement studies in 128·9 million children, adolescents, and adults. Lancet. 2017; 390: 2627‑2642. | Crossref
ARTICLE INFORMATION